India Non-alcoholic Steatohepatitis Treatment Market Size & Outlook
Related Markets
India non-alcoholic steatohepatitis treatment market highlights
- The India non-alcoholic steatohepatitis treatment market generated a revenue of USD 65.2 million in 2024 and is expected to reach USD 324.9 million by 2030.
- The India market is expected to grow at a CAGR of 30.9% from 2025 to 2030.
- In terms of segment, vitamin e and pioglitazone was the largest revenue generating drug in 2024.
- Lanifibranor is the most lucrative drug segment registering the fastest growth during the forecast period.
Non-alcoholic steatohepatitis treatment market data book summary
| Market revenue in 2024 | USD 65.2 million |
| Market revenue in 2030 | USD 324.9 million |
| Growth rate | 30.9% (CAGR from 2025 to 2030) |
| Largest segment | Vitamin e and pioglitazone |
| Fastest growing segment | Lanifibranor |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Vitamin E and Pioglitazone, Obeticholic Acid (OCA), Lanifibranor |
Other key industry trends
- In terms of revenue, India accounted for 0.8% of the global non-alcoholic steatohepatitis treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China non-alcoholic steatohepatitis treatment market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 324.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Non-alcoholic Steatohepatitis Treatment Market Scope
Non-alcoholic Steatohepatitis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Gilead Sciences, Inc. | View profile | - | - | - |
| NGM Biopharmaceuticals Inc. | View profile | - | - | - |
| Madrigal Pharmaceuticals | View profile | - | - | - |
| Galectin Therapeutics Inc. | View profile | - | - | - |
| Inventiva Pharma | View profile | - | - | - |
| Galmed Pharmaceuticals | View profile | - | - | - |
| Intercept Pharmaceuticals | View profile | - | - | - |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
India non-alcoholic steatohepatitis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis treatment market will help companies and investors design strategic landscapes.
Vitamin e and pioglitazone was the largest segment with a revenue share of 92.48% in 2024. Horizon Databook has segmented the India non-alcoholic steatohepatitis treatment market based on vitamin e and pioglitazone, obeticholic acid (oca), lanifibranor covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to India non-alcoholic steatohepatitis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India non-alcoholic steatohepatitis treatment market databook
-
Our clientele includes a mix of non-alcoholic steatohepatitis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India non-alcoholic steatohepatitis treatment market , including forecasts for subscribers. This country databook contains high-level insights into India non-alcoholic steatohepatitis treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
India non-alcoholic steatohepatitis treatment market size, by drug, 2018-2030 (US$M)
India Non-alcoholic Steatohepatitis Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
